HALO Halozyme Therapeutics Inc.

+0.17  (+1%)
Previous Close 16.11
Open 16.21
Price To Book 9.1
Market Cap 2,368,889,288
Shares 145,509,170
Volume 1,048,333
Short Ratio
Av. Daily Volume 821,837

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 data due by December 2019.
Pancreatic cancer
Approved September 12, 2014.
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.
PEGPH20 and atezolizumab
Phase 1b/2 data due late 2019 or early 2020.
BL-8040 in combination with TECENTRIQ (atezolizumab) and PEGPH20
Pancreatic cancer
FDA approval announced February 28, 2019.
Trastuzumab (Herceptin) using ENHANZE
Breast cancer
Regulatory filing due 2H 2019.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Phase 1 trial to commence 1Q 2020.
Autoimmune diseases

Latest News

  1. Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
  2. See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
  3. Edited Transcript of HALO earnings conference call or presentation 7-May-19 8:30pm GMT
  4. Is Halozyme Therapeutics, Inc. (HALO) A Good Stock To Buy?
  5. Halozyme To Participate In Upcoming Investor Conferences
  6. Is Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Balance Sheet Strong Enough To Weather A Storm?
  7. Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
  8. Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
  9. Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
  10. Halozyme Therapeutics Inc (HALO) Q1 2019 Earnings Call Transcript
  11. Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates
  12. Halozyme Therapeutics: 1Q Earnings Snapshot
  13. Halozyme Reports First Quarter 2019 Results
  14. Halozyme Therapeutics, Inc. to Host Earnings Call
  15. Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development
  16. How Halozyme Therapeutics, Inc. (NASDAQ:HALO) Can Impact Your Portfolio Volatility
  17. Here’s What Hedge Funds Think About Halozyme Therapeutics, Inc. (HALO) Anymore
  18. Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
  19. Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call